Home Blog Page 535

AIA Alta Prestige Wealth Centre Opens at AIA Central

Elevating the High-Net-Worth and Ultra-High Net-Worth Experience through Orchestrated Wealth and Legacy Advisory


HONG KONG SAR – Media OutReach Newswire – 14 March 2026 – AIA Hong Kong announced the opening of the AIA Alta Prestige Wealth Centre at AIA Central, marking a significant milestone in the evolution of AIA Alta, its exclusive proposition for High‑Net‑Worth (HNW)1 and Ultra‑High‑Net‑Worth (UHNW) customers2. Purpose‑built in Central, the Centre is housed within AIA Central—a landmark commercial building wholly owned by AIA Group—at the heart of the city’s financial district. The Centre is designed to serve customers with increasingly complex, multi‑market wealth, health and legacy planning needs through a highly integrated and personalised advisory experience.

Mr Lee Yuan Siong, AIA Group Chief Executive and President (fourth from left); Mr Jacky Chan, AIA Regional Chief Executive and Group Chief Distribution Officer (fourth from right); Mr Alger Fung, Chief Executive Officer, AIA Hong Kong & Macau (third from left); Ms Alice Liang, Chief Proposition & Healthcare Officer, AIA Hong Kong & Macau (third from right); Ms Amy Chan, Chief Agency Officer, AIA Hong Kong & Macau (second from left); Ms Myra Lee, Chief Financial Officer, AIA Hong Kong & Macau (second from right); Ms Melissa Wong, Chief Customer & Marketing Officer, AIA Hong Kong & Macau (first from left); and Ms Carol Li, Chief Life Officer (first from right), AIA Hong Kong & Macau, celebrated the opening of the AIA Alta Prestige Wealth Centre.
Mr Lee Yuan Siong, AIA Group Chief Executive and President (fourth from left); Mr Jacky Chan, AIA Regional Chief Executive and Group Chief Distribution Officer (fourth from right); Mr Alger Fung, Chief Executive Officer, AIA Hong Kong & Macau (third from left); Ms Alice Liang, Chief Proposition & Healthcare Officer, AIA Hong Kong & Macau (third from right); Ms Amy Chan, Chief Agency Officer, AIA Hong Kong & Macau (second from left); Ms Myra Lee, Chief Financial Officer, AIA Hong Kong & Macau (second from right); Ms Melissa Wong, Chief Customer & Marketing Officer, AIA Hong Kong & Macau (first from left); and Ms Carol Li, Chief Life Officer (first from right), AIA Hong Kong & Macau, celebrated the opening of the AIA Alta Prestige Wealth Centre.

Alice Liang, Chief Proposition & Healthcare Officer of AIA Hong Kong & Macau, said: “Since 2023, we have continued to strengthen our HNW proposition and see strong growth potential in this segment. In an increasingly dynamic global environment, enduring wealth, health and legacy planning have become more critical than ever.

Ms Alice Liang, Chief Proposition & Healthcare Officer of AIA Hong Kong & Macau, said that AIA Alta is extending its proposition to the UHNW segment, with the opening of the AIA Alta Prestige Wealth Centre marking a pivotal step in this journey.
Ms Alice Liang, Chief Proposition & Healthcare Officer of AIA Hong Kong & Macau, said that AIA Alta is extending its proposition to the UHNW segment, with the opening of the AIA Alta Prestige Wealth Centre marking a pivotal step in this journey.

We are elevating the HNW experience and expanding into the UHNW market as these customers seek more than insurance—looking for coordinated wealth and legacy advisory from a long-term partner who can guide them through complexity with clarity and confidence. The opening of the AIA Alta Prestige Wealth Centre is a pivotal step, supported by our HNW Dedicated Team and international partners, to help customers achieve an optimal balance of health and wealth.”

At the Heart of Hong Kong’s Financial District

Formerly known as the AIA Alta Wealth Management Centre in Causeway Bay, the Centre was established as the first# of its kind within Hong Kong’s insurance industry to provide professional wealth management services. Now housed within AIA Central, the AIA Alta Prestige Wealth Centre& offers unparalleled proximity to the city’s financial ecosystem. This strategic location enables seamless connection with private banks, professional firms and international institutions that play a critical role in multi‑market wealth structuring and legacy planning.

The AIA Alta Prestige Wealth Centre is designed to serve HNW and UHNW customers with increasingly complex, multi market wealth, health and legacy planning needs through a highly integrated and personalised advisory experience.(1)
The AIA Alta Prestige Wealth Centre is designed to serve HNW and UHNW customers with increasingly complex, multi market wealth, health and legacy planning needs through a highly integrated and personalised advisory experience.
The AIA Alta Prestige Wealth Centre is designed to serve HNW and UHNW customers with increasingly complex, multi market wealth, health and legacy planning needs through a highly integrated and personalised advisory experience.

A Refined Advisory Experience

The Centre has been purpose‑designed to deliver a more orchestrated and holistic advisory experience. Supported by AIA’s HNW Dedicated Team and a network of international organisations, HNW customers can access advisory services on trust, legacy, tax, legal and family office matters within a single private setting. By bringing these capabilities together across every stage of the wealth and legacy planning journey, the Centre reduces fragmentation and empowers customers to make more confident, informed decisions.

A distinctive feature of the Centre is its bespoke hospitality offering, with dining prepared by AIA’s own corporate dining team. Thoughtfully curated food and beverage selections complement advisory engagements within a calm and private environment. Visitors may also explore the History Wall, which traces AIA Group’s century‑long legacy in Asia and its enduring commitment to customers across generations, while enjoying panoramic views of Victoria Harbour, taking in Hong Kong’s iconic skyline and landmarks such as the Hong Kong Observation Wheel.

Guests can enjoy panoramic views of Victoria Harbour, taking in Hong Kong’s iconic skyline and landmarks.
Guests can enjoy panoramic views of Victoria Harbour, taking in Hong Kong’s iconic skyline and landmarks.

Purpose‑Led Design

Guided by AIA’s commitment to sustainability, the Centre’s design reflects ESG‑informed principles through material storytelling. Reclaimed elements—from ocean‑recovered fragments to repurposed glass, metal and wood—are thoughtfully re‑crafted to symbolise restoration, renewal and continuity, expressing AIA Alta’s belief that sustainability is a lived philosophy that preserves value, honours origins and supports enduring legacies across generations.

The Centre’s design reflects ESG informed principles through material storytelling.
The Centre’s design reflects ESG informed principles through material storytelling.

A Trusted Proposition for HNW Families

The strength of the AIA Alta proposition is underpinned by strong customer recognition. For years, AIA has been recognised as Hong Kong’s most popular insurance brand among HNW individuals%, reflecting sustained trust in its ability to support HNW families. Looking ahead, AIA Alta will continue to support customers through its integrated pillars of Wealth and Health, complemented by meaningful experiences and curated privileges offered through AIA Alta Club—empowering customers to truly live Healthier, Longer, Better Lives.

Visitors may also explore the History Wall, which traces AIA Group’s century long legacy in Asia and its enduring commitment to customers across generations.
Visitors may also explore the History Wall, which traces AIA Group’s century long legacy in Asia and its enduring commitment to customers across generations.
Remarks:
1 High‑Net‑Worth customer means a customer with investable wealth of US$1 million to US$30 million.
2 Ultra‑High‑Net‑Worth customer means a customer with investable wealth of more than US$30 million.
# As of 1 March 2023, compared with similar services offered by major Hong Kong insurance companies.
& AIA Alta Prestige Wealth Centre is available by invitation only.
% According to YouGov, an international research and data analytics company, Hong Kong BrandIndex 2022-2025, AIA has been the Most Considered Insurance Brand and is Most Likely to Be Purchased among the High-Net-Worth customers in Hong Kong (individuals with total investable assets exceeding US$ 1 million) for four consecutive years (from 2022 to 2025).

Important Information:
  • The above information provided herein shall not be construed as providing, selling, or soliciting the purchase of any insurance products or services outside Hong Kong and/or Macau, nor does it constitute any sales advice, product recommendation, or any form of service offer. Where the offering or sale of insurance products is prohibited under the laws of any jurisdiction outside Hong Kong and/or Macau, AIA shall not engage in such activities within that jurisdiction. AIA does not provide or sell insurance products or services in any territory other than Hong Kong and/or Macau. The above information is for reference purposes only and does not include detailed terms, conditions, or risk disclosures associated with the relevant products.
  • AIA reserves the right to amend, suspend or terminate the Services, any part thereof, service provider(s) or change any terms and conditions relating thereto at any time without prior notice at its absolute discretion.



Hashtag: #AIA

The issuer is solely responsible for the content of this announcement.

About AIA Hong Kong & Macau

AIA Group Limited established its operations in Hong Kong in 1931. To date, AIA Hong Kong and AIA Macau have about 18,000 financial planners*, as well as an extensive network of independent financial advisors, brokerage and bancassurance partners. We serve over 3.6 million customers^, offering them a wide selection of professional services and products ranging from individual life, group life, accident, medical and health, pension, personal lines insurance to investment-linked assurance schemes with numerous investment options. We are also dedicated to providing superb product solutions to meet the financial needs of high-net-worth customers.

* As at 30 June 2025
^ Including AIA Hong Kong and AIA Macau’s individual life, group insurance and pension customers (as at 30 June 2025)

China International Supply Chain Expo Unveils AI Zone as 100-Day Countdown Begins With 500+ Exhibitors

BEIJING, March 14, 2026 /PRNewswire/ — The fourth China International Supply Chain Expo (CISCE) has entered its 100-day countdown. Themed “Connecting the World for a Shared Future,” the event has evolved over three editions into an important platform for facilitating international cooperation across industrial and supply chains. Its model and value have extended well beyond China to help shape a global standard. The ISO 25639-1 international standard for “Exhibitions and Events—Vocabulary,” developed jointly by the global business community, explicitly incorporates the CISCE’s innovative approach and includes language reflecting the expo’s emphasis on connecting companies with potential partners across supply chains.


This year’s expo will mark a milestone with the launch of its first-ever Artificial Intelligence zone, offering a comprehensive look at the AI ecosystem encompassing data, computing power, and applications. Across its featured six supply chain sectors—Advanced Manufacturing, Clean Energy, Smart Vehicles, Digital Technology, Healthy Living, and Green Agriculture—alongside the Supply Chain Services Exhibition Area, visitors will encounter a lineup of new players—both Chinese and international—in emerging and future fields such as AI-enabled robotics, the drone and low-altitude aviation sector, and biomanufacturing, alongside established names showcasing the latest advances in industrial and supply chain modernization. Another new feature of the fourth CISCE will be an increased focus on targeted cooperation. Building on the previous “Guest Country of Honor” format, this year will introduce “Guest Provinces” for the first time, inviting overseas provinces, states, and regions with unique industrial advantages to participate and facilitate more targeted business matchmaking with Chinese provinces, cities, and companies.

Enthusiasm from the international business community remains high. At the third CISCE, exhibitors from outside China accounted for 35% of participants, with over 40 leaders from Fortune Global 500 companies and 172 delegations from abroad making dedicated trips to China for the expo. This reflects the strong interest of international businesses in supply chain partnerships and opportunities in the Chinese market. Preparations are moving forward smoothly. Nineteen international roadshows have already been held to present the expo around the world, with organizers aiming to achieve further growth in both the proportion of global exhibitors and the number of visiting delegations. More than 500 companies from China and around the world have already signed up to exhibit, and the recruitment phase is nearing completion.

For more information, please visit: https://en.cisce.org.cn/

Vimgreen’s Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy

HANGZHOU, China, March 14, 2026 /PRNewswire/ — Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic steatohepatitis (NASH), increasingly referred to as metabolic dysfunction‑associated steatohepatitis (MASH), by the China’s Center for Drug Evaluation (CDE). This achievement represents the second clinical indication for the company’s lead drug candidate, complementing its ongoing development program for Parkinson’s disease.

This approval constitutes the first global clearance of an A2A receptor antagonist for NASH clinical investigation. VG081821 can proceed directly to Phase II NASH trials, significantly shortening the clinical development timeline for this potential breakthrough therapy.

NASH is a progressive liver disease characterized by excessive fat accumulation (steatosis), hepatocellular injury, inflammation, and progressive fibrosis. With obesity and metabolic syndrome reaching epidemic proportions worldwide, NASH has emerged as a leading cause of cirrhosis and hepatocellular carcinoma. Despite its increasing prevalence and severe clinical consequences, the therapeutic landscape remains highly limited: to date, only two pharmacological agents—resmetirom and semaglutide—have been granted merely accelerated approval, underscoring a critical unmet need for additional effective treatment options.

As an A2A receptor antagonist, VG081821 simultaneously targets the three core pathological features of NASH: steatosis, inflammation, and fibrosis. Given the complex pathophysiology of NASH, this multi-dimensional therapeutic approach offers distinct advantages, positioning VG081821 as a highly promising candidate for NASH therapy.

Compelling epidemiological evidence strongly supports the therapeutic potential of A2AR antagonists for NASH. Multiple large-scale studies have shown that moderate coffee consumption significantly reduces the risk of chronic liver disease. Caffeine, coffee’s primary bioactive compound, exerts hepatoprotective effects primarily through A2A receptor inhibition. As a significantly more potent and selective A2A receptor antagonist than caffeine, VG081821 is designed to deliver these proven benefits with enhanced therapeutic precision.

VG081821 distinguishes itself from traditional A2A receptor antagonists such as istradefylline through its unique pharmacological profile. While conventional antagonists simply block receptor activation, VG081821—the only A2A inverse agonist currently in global clinical development—further suppresses the receptor’s constitutive basal activity. This dual mechanism enables more complete inhibition of pathological signaling, potentially delivering superior pharmacological effects compared to standard antagonists.

VG081821’s first indication is Parkinson’s disease, where it represents the only investigational therapy globally that addresses both symptoms and underlying disease mechanisms. In completed Phase II trials of early-to-mid-stage Parkinson’s disease, VG081821 demonstrated significant improvements in motor function, meeting all efficacy expectations and showing strong potential as a monotherapy. The primary observed adverse event was transient elevation of liver transaminases—likely a pharmacological consequence of accelerated hepatic de-lipidation and enhanced gluconeogenesis (a processes requiring transaminase participation) rather than a toxic effect. Similar transient transaminase elevations have been observed with other lipid-modifying agents, including fibrates and resmetirom (for NASH), and are generally considered benign adaptive physiological responses. This finding further validates the expected pharmacological effects of VG081821 from an alternative perspective.

“We are thrilled to receive the IND approval to advance VG081821 for NASH therapy,” said Sanxing Sun, President and CEO of Vimgreen Pharmaceuticals. “Its mechanism of action is highly differentiated from current THR-beta agonists and GLP-1 therapies. By leveraging the drug’s unique ability to restore hepatic lipophagy while simultaneously resolving inflammation and fibrosis, we are well-positioned to address the substantial unmet need in metabolic liver diseases and poised to deliver superior patient outcomes.”

Vimgreen expects to initiate a Phase IIa trial for NASH treatment in the second half of the year.

About Vimgreen Pharmaceuticals

Vimgreen is a clinical-stage pharmaceutical company based in Hangzhou, China. The company is dedicated to developing novel therapeutics targeting adenosine signaling pathways, with a focus on addressing unmet medical needs in neurodegenerative, metabolic, and inflammatory diseases. Vimgreen’s pipeline includes two clinical-stage compounds: VG081821, an A2A receptor antagonist for Parkinson’s disease and NASH; and VG290131, an A3 receptor agonist for autoimmune and inflammatory diseases.

Forward Looking Statements

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “expects,” “may,” “will,” “should,” “potential,” and similar expressions are intended to identify forward-looking statements. These statements involve predictions, projections, and other expectations about future events that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements due to various factors, including Vimgreen’s ability to execute its commercial strategy and successfully complete clinical development. Forward-looking statements speak only as of the date made. Vimgreen undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.

Vimgreen’s Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy

HANGZHOU, China, March 14, 2026 /PRNewswire/ — Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic steatohepatitis (NASH), increasingly referred to as metabolic dysfunction‑associated steatohepatitis (MASH), by the China’s Center for Drug Evaluation (CDE). This achievement represents the second clinical indication for the company’s lead drug candidate, complementing its ongoing development program for Parkinson’s disease.

This approval constitutes the first global clearance of an A2A receptor antagonist for NASH clinical investigation. VG081821 can proceed directly to Phase II NASH trials, significantly shortening the clinical development timeline for this potential breakthrough therapy.

NASH is a progressive liver disease characterized by excessive fat accumulation (steatosis), hepatocellular injury, inflammation, and progressive fibrosis. With obesity and metabolic syndrome reaching epidemic proportions worldwide, NASH has emerged as a leading cause of cirrhosis and hepatocellular carcinoma. Despite its increasing prevalence and severe clinical consequences, the therapeutic landscape remains highly limited: to date, only two pharmacological agents—resmetirom and semaglutide—have been granted merely accelerated approval, underscoring a critical unmet need for additional effective treatment options.

As an A2A receptor antagonist, VG081821 simultaneously targets the three core pathological features of NASH: steatosis, inflammation, and fibrosis. Given the complex pathophysiology of NASH, this multi-dimensional therapeutic approach offers distinct advantages, positioning VG081821 as a highly promising candidate for NASH therapy.

Compelling epidemiological evidence strongly supports the therapeutic potential of A2AR antagonists for NASH. Multiple large-scale studies have shown that moderate coffee consumption significantly reduces the risk of chronic liver disease. Caffeine, coffee’s primary bioactive compound, exerts hepatoprotective effects primarily through A2A receptor inhibition. As a significantly more potent and selective A2A receptor antagonist than caffeine, VG081821 is designed to deliver these proven benefits with enhanced therapeutic precision.

VG081821 distinguishes itself from traditional A2A receptor antagonists such as istradefylline through its unique pharmacological profile. While conventional antagonists simply block receptor activation, VG081821—the only A2A inverse agonist currently in global clinical development—further suppresses the receptor’s constitutive basal activity. This dual mechanism enables more complete inhibition of pathological signaling, potentially delivering superior pharmacological effects compared to standard antagonists.

VG081821’s first indication is Parkinson’s disease, where it represents the only investigational therapy globally that addresses both symptoms and underlying disease mechanisms. In completed Phase II trials of early-to-mid-stage Parkinson’s disease, VG081821 demonstrated significant improvements in motor function, meeting all efficacy expectations and showing strong potential as a monotherapy. The primary observed adverse event was transient elevation of liver transaminases—likely a pharmacological consequence of accelerated hepatic de-lipidation and enhanced gluconeogenesis (a processes requiring transaminase participation) rather than a toxic effect. Similar transient transaminase elevations have been observed with other lipid-modifying agents, including fibrates and resmetirom (for NASH), and are generally considered benign adaptive physiological responses. This finding further validates the expected pharmacological effects of VG081821 from an alternative perspective.

“We are thrilled to receive the IND approval to advance VG081821 for NASH therapy,” said Sanxing Sun, President and CEO of Vimgreen Pharmaceuticals. “Its mechanism of action is highly differentiated from current THR-beta agonists and GLP-1 therapies. By leveraging the drug’s unique ability to restore hepatic lipophagy while simultaneously resolving inflammation and fibrosis, we are well-positioned to address the substantial unmet need in metabolic liver diseases and poised to deliver superior patient outcomes.”

Vimgreen expects to initiate a Phase IIa trial for NASH treatment in the second half of the year.

About Vimgreen Pharmaceuticals

Vimgreen is a clinical-stage pharmaceutical company based in Hangzhou, China. The company is dedicated to developing novel therapeutics targeting adenosine signaling pathways, with a focus on addressing unmet medical needs in neurodegenerative, metabolic, and inflammatory diseases. Vimgreen’s pipeline includes two clinical-stage compounds: VG081821, an A2A receptor antagonist for Parkinson’s disease and NASH; and VG290131, an A3 receptor agonist for autoimmune and inflammatory diseases.

Forward Looking Statements

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “expects,” “may,” “will,” “should,” “potential,” and similar expressions are intended to identify forward-looking statements. These statements involve predictions, projections, and other expectations about future events that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements due to various factors, including Vimgreen’s ability to execute its commercial strategy and successfully complete clinical development. Forward-looking statements speak only as of the date made. Vimgreen undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.

Vimgreen’s Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy

HANGZHOU, China, March 14, 2026 /PRNewswire/ — Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic steatohepatitis (NASH), increasingly referred to as metabolic dysfunction‑associated steatohepatitis (MASH), by the China’s Center for Drug Evaluation (CDE). This achievement represents the second clinical indication for the company’s lead drug candidate, complementing its ongoing development program for Parkinson’s disease.

This approval constitutes the first global clearance of an A2A receptor antagonist for NASH clinical investigation. VG081821 can proceed directly to Phase II NASH trials, significantly shortening the clinical development timeline for this potential breakthrough therapy.

NASH is a progressive liver disease characterized by excessive fat accumulation (steatosis), hepatocellular injury, inflammation, and progressive fibrosis. With obesity and metabolic syndrome reaching epidemic proportions worldwide, NASH has emerged as a leading cause of cirrhosis and hepatocellular carcinoma. Despite its increasing prevalence and severe clinical consequences, the therapeutic landscape remains highly limited: to date, only two pharmacological agents—resmetirom and semaglutide—have been granted merely accelerated approval, underscoring a critical unmet need for additional effective treatment options.

As an A2A receptor antagonist, VG081821 simultaneously targets the three core pathological features of NASH: steatosis, inflammation, and fibrosis. Given the complex pathophysiology of NASH, this multi-dimensional therapeutic approach offers distinct advantages, positioning VG081821 as a highly promising candidate for NASH therapy.

Compelling epidemiological evidence strongly supports the therapeutic potential of A2AR antagonists for NASH. Multiple large-scale studies have shown that moderate coffee consumption significantly reduces the risk of chronic liver disease. Caffeine, coffee’s primary bioactive compound, exerts hepatoprotective effects primarily through A2A receptor inhibition. As a significantly more potent and selective A2A receptor antagonist than caffeine, VG081821 is designed to deliver these proven benefits with enhanced therapeutic precision.

VG081821 distinguishes itself from traditional A2A receptor antagonists such as istradefylline through its unique pharmacological profile. While conventional antagonists simply block receptor activation, VG081821—the only A2A inverse agonist currently in global clinical development—further suppresses the receptor’s constitutive basal activity. This dual mechanism enables more complete inhibition of pathological signaling, potentially delivering superior pharmacological effects compared to standard antagonists.

VG081821’s first indication is Parkinson’s disease, where it represents the only investigational therapy globally that addresses both symptoms and underlying disease mechanisms. In completed Phase II trials of early-to-mid-stage Parkinson’s disease, VG081821 demonstrated significant improvements in motor function, meeting all efficacy expectations and showing strong potential as a monotherapy. The primary observed adverse event was transient elevation of liver transaminases—likely a pharmacological consequence of accelerated hepatic de-lipidation and enhanced gluconeogenesis (a processes requiring transaminase participation) rather than a toxic effect. Similar transient transaminase elevations have been observed with other lipid-modifying agents, including fibrates and resmetirom (for NASH), and are generally considered benign adaptive physiological responses. This finding further validates the expected pharmacological effects of VG081821 from an alternative perspective.

“We are thrilled to receive the IND approval to advance VG081821 for NASH therapy,” said Sanxing Sun, President and CEO of Vimgreen Pharmaceuticals. “Its mechanism of action is highly differentiated from current THR-beta agonists and GLP-1 therapies. By leveraging the drug’s unique ability to restore hepatic lipophagy while simultaneously resolving inflammation and fibrosis, we are well-positioned to address the substantial unmet need in metabolic liver diseases and poised to deliver superior patient outcomes.”

Vimgreen expects to initiate a Phase IIa trial for NASH treatment in the second half of the year.

About Vimgreen Pharmaceuticals

Vimgreen is a clinical-stage pharmaceutical company based in Hangzhou, China. The company is dedicated to developing novel therapeutics targeting adenosine signaling pathways, with a focus on addressing unmet medical needs in neurodegenerative, metabolic, and inflammatory diseases. Vimgreen’s pipeline includes two clinical-stage compounds: VG081821, an A2A receptor antagonist for Parkinson’s disease and NASH; and VG290131, an A3 receptor agonist for autoimmune and inflammatory diseases.

Forward Looking Statements

Certain statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “expects,” “may,” “will,” “should,” “potential,” and similar expressions are intended to identify forward-looking statements. These statements involve predictions, projections, and other expectations about future events that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements due to various factors, including Vimgreen’s ability to execute its commercial strategy and successfully complete clinical development. Forward-looking statements speak only as of the date made. Vimgreen undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.

Cherry Blossoms Aren’t the Only Thing in Full Bloom This Spring: CASEKOO Debuts LinKOO, the World’s First Open Clasp System

LOS ANGELES, March 14, 2026 /PRNewswire/ — CASEKOO, a leader in innovative mobile lifestyle accessories, today announced the launch of LinKOO, a groundbreaking phone case featuring the world’s first open clasp system. Celebrating the vibrant energy and happiness of Spring, LinKOO is designed for the season’s getaways, outdoor adventures, and everyday moments of delight.

Revolutionary design offers ultimate versatility, allowing the clasp to fold away seamlessly when not in use.
Revolutionary design offers ultimate versatility, allowing the clasp to fold away seamlessly when not in use.

The magic of LinKOO happens when the chain comes off. Engineered with a patented clasp at the base of the case, it securely holds a chain or wristlet to complement any spring look. But the true innovation? The clasp folds completely flat against the phone when not in use—instantly transforming from a statement accessory into a sleek, pocket-friendly case built for life in motion.

“Spring represents a time of renewal and reconnection, so we designed LinKOO to be the perfect companion for the season’s adventures,” said Ralph, founder of CASEKOO. “We’ve engineered a clasp that simply ‘disappears’ when you don’t need it—giving our community the freedom to move seamlessly from a morning run to an afternoon of shopping, all while keeping their style and their phone protected. But what truly excites us is how LinKOO sparks curiosity. It’s designed to be noticed—inviting others to come closer, to ask what it is, and to start a conversation. Because the best connections happen when we’re open to them.”

A Joyful, Adventure-Ready Design
Just as the season calls for versatility and a touch of whimsy, the LinKOO case is built to adapt. Key features include:

World’s First Open Clasp System: A unique, hinged clasp that opens to hold a chain and closes to lay flush against the case, offering a clean, uninterrupted profile.

Transformative 2-in-1 Design: Effortlessly switches between a secure chain-carry mode for hands-free convenience and a compact traditional case for slipping into a pocket or bag.

Spring-Ready Style & Protection: Constructed with a durable, impact-resistant frame and available in a range of fresh, seasonal colors and finishes to match any spring wardrobe.

Interchangeable Chain Compatibility: Works seamlessly with CASEKOO’s collection of chains and straps, allowing users to mix and match for a personalized look that fits every spring adventure.

Playful Extras & Availability
Embracing the spirit of discovery, the LinKOO launch invites users to refresh their style for the new season. The CASEKOO LinKOO case is now available in Vital Orange for the iPhone 17 Pro Max, with a full range of colors and finishes rolling out in late May. To inspire endless mix-and-match possibilities, complementary straps are currently included with every LinKOO case purchase.

About CASEKOO
CASEKOO is a design-led lifestyle brand dedicated to creating style-forward phone accessories for life in motion. Built for Innovation Enthusiasts and Style Pioneers, the brand blends purposeful protection with modern design and personal expression—empowering individuals to protect what matters while expressing who they are.

Learn more at casekoo.com.

 

Cherry Blossoms Aren’t the Only Thing in Full Bloom This Spring: CASEKOO Debuts LinKOO, the World’s First Open Clasp System

LOS ANGELES, March 14, 2026 /PRNewswire/ — CASEKOO, a leader in innovative mobile lifestyle accessories, today announced the launch of LinKOO, a groundbreaking phone case featuring the world’s first open clasp system. Celebrating the vibrant energy and happiness of Spring, LinKOO is designed for the season’s getaways, outdoor adventures, and everyday moments of delight.

Revolutionary design offers ultimate versatility, allowing the clasp to fold away seamlessly when not in use.
Revolutionary design offers ultimate versatility, allowing the clasp to fold away seamlessly when not in use.

The magic of LinKOO happens when the chain comes off. Engineered with a patented clasp at the base of the case, it securely holds a chain or wristlet to complement any spring look. But the true innovation? The clasp folds completely flat against the phone when not in use—instantly transforming from a statement accessory into a sleek, pocket-friendly case built for life in motion.

“Spring represents a time of renewal and reconnection, so we designed LinKOO to be the perfect companion for the season’s adventures,” said Ralph, founder of CASEKOO. “We’ve engineered a clasp that simply ‘disappears’ when you don’t need it—giving our community the freedom to move seamlessly from a morning run to an afternoon of shopping, all while keeping their style and their phone protected. But what truly excites us is how LinKOO sparks curiosity. It’s designed to be noticed—inviting others to come closer, to ask what it is, and to start a conversation. Because the best connections happen when we’re open to them.”

A Joyful, Adventure-Ready Design
Just as the season calls for versatility and a touch of whimsy, the LinKOO case is built to adapt. Key features include:

World’s First Open Clasp System: A unique, hinged clasp that opens to hold a chain and closes to lay flush against the case, offering a clean, uninterrupted profile.

Transformative 2-in-1 Design: Effortlessly switches between a secure chain-carry mode for hands-free convenience and a compact traditional case for slipping into a pocket or bag.

Spring-Ready Style & Protection: Constructed with a durable, impact-resistant frame and available in a range of fresh, seasonal colors and finishes to match any spring wardrobe.

Interchangeable Chain Compatibility: Works seamlessly with CASEKOO’s collection of chains and straps, allowing users to mix and match for a personalized look that fits every spring adventure.

Playful Extras & Availability
Embracing the spirit of discovery, the LinKOO launch invites users to refresh their style for the new season. The CASEKOO LinKOO case is now available in Vital Orange for the iPhone 17 Pro Max, with a full range of colors and finishes rolling out in late May. To inspire endless mix-and-match possibilities, complementary straps are currently included with every LinKOO case purchase.

About CASEKOO
CASEKOO is a design-led lifestyle brand dedicated to creating style-forward phone accessories for life in motion. Built for Innovation Enthusiasts and Style Pioneers, the brand blends purposeful protection with modern design and personal expression—empowering individuals to protect what matters while expressing who they are.

Learn more at casekoo.com.

 

Higgsfield Launches Similarity-Scoring Tool for Responsible AI Use in Media and Entertainment

As the generative AI industry matures, Higgsfield is taking an important step towards equipping creators and studios with a new tool designed to help assess potential similarity with characters, celebrity likeness, and brands.

SAN FRANCISCO, March 14, 2026 /PRNewswire/ — Higgsfield, the AI-native video and image platform for professional creators, announced the launch of a similarity-scoring feature for Team Plan customers. The tool evaluates AI-generated content and flags potential visual similarities to celebrity likenesses, characters, brand logos, and other potential intellectual property.

The feature arrives as Higgsfield’s platform scales rapidly into commercial production. The company has doubled its user base in under two months, surpassing 20 million users, with a growing share of usage now coming from production teams running commercial campaigns. As AI-generated content moves deeper into professional workflows and elite festivals, creators and teams are increasingly expected to consider similarity, likeness, and whether a generated asset may resemble something protected.

Despite this rapid mainstream adoption, the lack of standardized safeguards remains a bottleneck for wider commercial use. Recognizing this industry-wide challenge, Higgsfield is introducing new features that empower users to make safer choices when using AI generated assets.

The new tool evaluates generated content and assigns it a similarity score to help users identify potential conflicts. Going beyond basic detection, Higgsfield’s system is designed to be more nuanced than existing market solutions. The feature evaluates content to known properties, including:

  • Characters from popular movies, TV, and video games (e.g., Harry Potter, Spider-Man).
  • Likeness of public figures, including stylistic alterations (e.g., a celebrity rendered in unusual forms or wearing obscuring props).
  • Brand logos and text assets, such as trademarked taglines.
  • Famous artworks and distinct visual concepts.
  • Cinematic signatures, such as distinct visual styles associated with specific directors or films (e.g., Wes Anderson, Denis Villeneuve, Alfred Hitchcock).
  • Audio content, such as music and other audio content incorporated into video output.

Higgsfield's Content Scoring System
Higgsfield’s Content Scoring System

To validate the system’s efficacy, the Higgsfield Research Team conducted internal benchmark studies across diverse datasets of AI-generated and reference media. In video detection, Higgsfield’s model achieved an 86.6% overall accuracy rate. Higgsfield also significantly reduced false positive rates, flagging incorrect similarities in video only 13.4% of the time.

When a potential similarity is detected, the tool identifies the nature of the similarity, the possible rights holder, and exactly where the similarity occurs in the video. Building on this initiative, Higgsfield has also launched an image model “Soul Cast”, which limits image reference uploads, reducing the risk of generating someone else’s likeness.

“Generative video is still a new frontier and studios, platforms, and policy experts are all still navigating the complexities of IP and likeness,” said Higgsfield CEO Alex Mashrabov. “By activating our content-scoring feature, we give creators a practical way to understand their outputs before final production. We believe that proactive similarity tools like this will soon become standard across the entire generative AI ecosystem.”

Higgsfield’s initiative reflects a broader company commitment to the ethical and responsible commercialization of AI. For example, the company recently launched the Higgsfield Action Contest with a $500,000 prize pool, accepting nearly 8,800 submissions from all over the world. Content safety is integral to the review process along with originality and storytelling as part of the company’s broader approach to building responsibly in this emerging space.

By building tools that empower human creativity while respecting intellectual property, Higgsfield aims to encourage the responsible use of AI technologies.

For more information about Higgsfield’s new content-scoring feature, visit https://higgsfield.ai/app/similarity-score.

About Higgsfield

Higgsfield is an AI-native generative video platform built for professional creators, brands, agencies, and marketing teams producing high-fidelity videos at scale. The company develops its own generative video and image models and integrates leading third-party models such as OpenAI’s Sora, Google’s Veo and Nano Banana, Alibaba’s WAN, Kuaishou’s Kling, Bytedance’s Seedream and Seedance, MiniMax, and others into a single, production-ready workflow, allowing teams to select the best model for each creative task without rebuilding pipelines.